Pharma R&D and Biotech Innovation - Dr. Craig Crews, Yale

​Join us for a moderated conversation with Dr. Craig Crews, John C. Malone Professor of Molecular, Cellular, and Developmental Biology at Yale. Dr. Crews will share insights on recent biotech innovations and pharmaceutical research and development. This is an exceptional opportunity to learn about the cutting edge. All Yale students are welcome!

​About Dr. Crews

​Dr. Craig Crews is a Yale University professor and pioneering chemical biologist whose work has reshaped drug discovery. He co-founded Proteolix, whose proteasome inhibitor led to the multiple myeloma drug Kyprolis and was acquired by Onyx Pharmaceuticals in 2009. Building on his foundational research in targeted protein degradation and PROTACs, Crews also founded Arvinas, advancing novel therapies into clinical trials. Most recently, his Connecticut-based biotech, Halda Therapeutics, which focused on innovative cancer treatments, was acquired by Johnson & Johnson in a landmark deal valued at approximately $3 billion in 2025, underscoring his impact on translating basic science into transformative medicines.